AIMT stock news

BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2019 Financial Results and Recent Operational Read more
Aimmune (AIMT) is likely to provide an update on Palforzia's launch plans during Q4 investors' call. The drug gets an approval in January 2020 for the treatment of peanut allergy. Read more
Aimmune Therapeutics Inc (NASDAQ: AIMT ) recently received FDA approval for its peanut allergy drug Palforzia. The Aimmune Analyst Baird analyst Brian Skorney maintained an Outperform rating on Aimmune with a $64 price target. The Aimmune Thesis With NESTLE S A/S ADR (OTC: NSRGY ) Health Science's $200-million investment in Aimmune, the company is now adequately funded for the Palforzia launch, settling the bull-bear launch debate, Skorney said in a Thursday note. (See his track record here .) The Nestle investment, along with Aimmune's existing cash and KKR credit facility, places more than $450 million at Aimmune's disposal, the analyst said. "Given this significant liquidity, we do not believe the company will need to raise additional capital in the near-term, essentially eliminating the ability … Full story available on Read more
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that Nestlé Health Science will make an additional equity investment in Aimmune of $200 million, bringing Nestlé’s total investment in Aimmune to date to $473 million. “Nestlé Health Science has been an important equity investor and strategic partner to Aimmune since we entered into ou Read more
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced it has obtained an exclusive worldwide license to develop and commercialize the investigational humanized monoclonal antibody XmAb®7195 from Xencor, Inc. XmAb7195, which has been renamed AIMab7195, was originally developed by Xencor for the treatment of allergic asthma. It uses three distinct mechanisms o Read more
Aimmune Therapeutics Inc (NASDAQ: AIMT ) announced late Friday that it received FDA approval for Palforzia , its oral immunotherapy to treat peanut allergy. The Aimmune Analysts Baird analyst Brian Skorney maintained an Outperform rating and $64 price target for Aimmune shares. RBC Capital Markets analyst Kennen MacKay has an Outperform rating and $54 price target. Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating and lifted the price target from $55 to $64. Baird: Palforzia Will Experience Strong Uptake The clean label of Palforzia and the management's well-informed launch plan are encouraging, Baird analyst Skorney said in a Monday note. The clean label with respect to the age group of the patient population, no surprises in with the black box labelling and the 60-minute monitoring period following dose escalation should help facilitate strong product launch, the analyst said. "With 1.6 million patients in the U.S. estimated to have peanut allergies and no previously approved treatments, we believe this market represents an area of significant unmet need." The analyst projects strong uptake that will be facilitated by … Read more
The FDA cleared the drug Palforzia; it is the first peanut allergy drug that is safe for kids. Dr. Jayson Dallas, Aimmune Therapeutics CEO & President shares the details with Yahoo Finance's On The Move. Read more
Aimmune Therapeutics stock surged ahead of market open Monday, after the FDA announced Friday it had approved Aimmune's peanut allergy treatment for children. It's the first such treatment to gain approval from the FDA. Shares jumped as much as 17% Monday morning. Visit Business Insider's homepage for more stories . The Food and Drug Administration has approved for the first time a drug that treats peanut allergies in children. That sent shares of Aimmune Therapeutics — the maker of the new treatment — flying. Shares jumped as high as 17% in early trading on Monday. The drug, called Palforzia, aims to reduce the effects of unintentional peanut exposure, the company said in a statement Friday. Patients between the ages of 4 and 17 are eligible to begin the treatment, according to the Food and Drug Administraton. Antihistamines and epi-pens can be used to treat a sudden allergic reaction, the FDA said in a Friday statement, but they are not always enough to mitigate a severe reaction. "Palforzia provides an FDA-approved treatment option to help reduce the risk of these allergic reactions in children with peanut allergy," Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, said in the statement . Read more
Aimmune Therapeutics says the US Food and Drug Administration has approved its drug to reduce, and potentially eliminate, allergic reactions to peanuts in children aged 4 to 17. Read more
Palforzia Allergen Powder by Aimmune Therapeutics is for kids 4 to 17 who are accidentally exposed. Read more
Shares of biopharma Aimmune Therapeutics Inc (NASDAQ: AIMT ) advanced strongly in after-hours trading Friday following a positive FDA verdict for Aimunne's peanut allergy drug. 9-Year Wait Ends The FDA approved Palforzia allergen powder for treating patients with confirmed diagnosis of peanut allergy, the Brisbane, California-based company said in a late Friday release. This is the first commercial success for the company, which was founded in 2011 and is working exclusively on therapies for food allergies. An FDA panel, which reviewed the BLA for Palforzia back in September, voted 7-2, recommending the approval on the grounds of efficacy and safety. See Also: Biotech Stock On The Radar: Aimmune Awaits Adcom Test Palforzia is an oral immunotherapy meant to mitigate allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The mechanism of action goes like this: the allergenic proteins are taken initially in small quantities, following by increasing amounts of ingestion, which helps mitigation of allergic reactions to the allergen over time. Read more

FDA Approves First Drug for Peanut Allergy

10:44pm, Friday, 31'st Jan 2020
The treatment from Aimmune Therapeutics provides a new option for the growing number of children and their families dealing with the life-threatening condition. Read more
Shares of Aimmune Therapeutics Inc. rose more than 12% in the extended session Friday after the Brisbane, Calif., company said the FDA has approved one of… Read more
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that the U.S. Food and Drug Administration (FDA) approved PALFORZIA™ [Peanut (Arachis hypogaea) Allergen Powder-dnfp]. PALFORZIA is the first approved treatment for patients with peanut allergy. It is an oral immunotherapy indicated for the mitigation of allergic reactions, including a Read more
Biotech stocks haven't seen much of a momentum thus far in the new year amid a lack of meaningful catalysts. The bygone week saw two FDA approvals: Horizon Therapeutics PLC's (NASDAQ: HZNP ) thyroid eye disorder drug and Epizyme Inc's (NASDAQ: EPZM ) tazemetostat for epithelioid sarcoma. The Wuhan coronavirus scare triggered strong moves in stocks of companies working on treatment/vaccines for the deadly virus. Here are the key catalysts that could impact trading in biotech stocks in the unfolding week. Conferences 12th Annual T-cell Lymphoma Forum: Jan. 30–Feb. 1 in San Diego, California PDUFA Dates Aimmune Therapeutics Inc (NASDAQ: AIMT ) has a target action date of end of January for its peanut allergy treatment candidate Palforzia . An Adcom that evaluated the experimental therapy voted 7-to-2 in favor of the efficacy of Palforzia and 8-to-1 in favor of its … Full story available on Read more

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

Proudly Made At